<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02129803</url>
  </required_header>
  <id_info>
    <org_study_id>HM20002205</org_study_id>
    <nct_id>NCT02129803</nct_id>
  </id_info>
  <brief_title>Evaluating High Flow Humidification Therapy in Patients With Cystic Fibrosis</brief_title>
  <official_title>Evaluating High Flow Humidification Therapy in Patients With Cystic Fibrosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Virginia Commonwealth University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Virginia Commonwealth University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is a single center, randomized pilot study to evaluate the clinical effectiveness&#xD;
      of nasal high flow 20LPM humidification therapy in subjects with Cystic Fibrosis.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2015</start_date>
  <completion_date type="Actual">May 29, 2019</completion_date>
  <primary_completion_date type="Actual">May 29, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Cystic Fibrosis Questionnaire-Revised (CFQ-R)</measure>
    <time_frame>Day 0 to Day 6 or upon discharge from the hospital, whichever comes first</time_frame>
    <description>The Cystic Fibrosis Questionnaire-Revised (CFQ-R) is a validated health-related quality of life measure for CF that meets US Food and Drug Administration psychometric requirements for patient reported outcomes. It contains both generic and CF-specific scales and has demonstrated responsiveness in previous clinical studies. Scores range from 0 to 100 with higher scores indicating better health.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Sputum Collection</measure>
    <time_frame>10 minutes</time_frame>
    <description>Sputum is collected during pulmonary function test (PFT) to later measure the biophysical properties of cystic fibrosis sputum.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Cystic Fibrosis</condition>
  <arm_group>
    <arm_group_label>Experimental Therapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>High-Flow, 20 LPM (via Optiflow cannula) Heated (34C) Humidified Air</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control Therapy (Low Flow)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Low FLow, 5 LPM (via Optiflow cannula) Room Temperature (23-26C) Ambient Air</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>High-Flow, 20 LPM (via Optiflow cannula)</intervention_name>
    <description>Nasal high flow humidification (20LPM) therapy will be administered using Optiflow with Airvo 2.</description>
    <arm_group_label>Experimental Therapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Low FLow, 5 LPM (via Optiflow cannula)</intervention_name>
    <description>standard humidified wall medical air.</description>
    <arm_group_label>Control Therapy (Low Flow)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Confirmed diagnosis of CF&#xD;
&#xD;
          -  Hospital admission for acute pulmonary exacerbation of CF (using Fuchs criteria 4/10)&#xD;
&#xD;
          -  10 years of age and older&#xD;
&#xD;
          -  Subject is able to comply with the procedures scheduled in the protocol&#xD;
&#xD;
          -  Signed informed consent form&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Receipt of any aerosolized experimental or investigational drugs within 1 month of&#xD;
             enrollment&#xD;
&#xD;
          -  Subject had ear, nose, and throat (ENT) surgery, nasal bleeding, or nasal polyps&#xD;
             within 6 months prior to study&#xD;
&#xD;
          -  Subject is unlikely to comply with the procedures scheduled in the protocol&#xD;
&#xD;
          -  Inability to give informed consent&#xD;
&#xD;
          -  Subject requires supplemental oxygen&#xD;
&#xD;
          -  History of obstructive sleep apnea&#xD;
&#xD;
          -  History of pressure headaches requiring therapy within one month of enrollment&#xD;
&#xD;
          -  Any other medical or psychological condition in which the study doctor(s) believe(s)&#xD;
             would inhibit the individual from being an appropriate study subject.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>10 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bruce K Rubin, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Virginia Commonwealth University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Children's Hospital of Richmond at VCU</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23298</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>April 10, 2014</study_first_submitted>
  <study_first_submitted_qc>May 1, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 2, 2014</study_first_posted>
  <results_first_submitted>November 30, 2020</results_first_submitted>
  <results_first_submitted_qc>January 4, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">January 6, 2021</results_first_posted>
  <disposition_first_submitted>April 28, 2020</disposition_first_submitted>
  <disposition_first_submitted_qc>May 1, 2020</disposition_first_submitted_qc>
  <disposition_first_posted type="Actual">May 7, 2020</disposition_first_posted>
  <last_update_submitted>January 4, 2021</last_update_submitted>
  <last_update_submitted_qc>January 4, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 6, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Cystic Fibrosis, high flow 20 liters per minute (LPM) humidification therapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cystic Fibrosis</mesh_term>
    <mesh_term>Fibrosis</mesh_term>
  </condition_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>May 25, 2016</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/03/NCT02129803/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Experimental Therapy</title>
          <description>High-Flow, 20 LPM (via Optiflow cannula) Heated (34C) Humidified Air&#xD;
High-Flow, 20 LPM (via Optiflow cannula): Nasal high flow humidification (20LPM) therapy will be administered using Optiflow with Airvo 2.</description>
        </group>
        <group group_id="P2">
          <title>Control Therapy (Low Flow)</title>
          <description>Low FLow, 5 LPM (via Optiflow cannula) Room Temperature (23-26C) Ambient Air&#xD;
Low FLow, 5 LPM (via Optiflow cannula): standard humidified wall medical air.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="9"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Difficulty sleeping</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Morning headache</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Experimental Therapy</title>
          <description>High-Flow, 20 LPM (via Optiflow cannula) Heated (34C) Humidified Air&#xD;
High-Flow, 20 LPM (via Optiflow cannula): Nasal high flow humidification (20LPM) therapy will be administered using Optiflow with Airvo 2.</description>
        </group>
        <group group_id="B2">
          <title>Control Therapy (Low Flow)</title>
          <description>Low FLow, 5 LPM (via Optiflow cannula) Room Temperature (23-26C) Ambient Air&#xD;
Low FLow, 5 LPM (via Optiflow cannula): standard humidified wall medical air.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="12"/>
            <count group_id="B2" value="12"/>
            <count group_id="B3" value="24"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="19.4" spread="5.4"/>
                    <measurement group_id="B2" value="21.7" spread="6.7"/>
                    <measurement group_id="B3" value="20.5" spread="6.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="13"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="23"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="17"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in Cystic Fibrosis Questionnaire-Revised (CFQ-R)</title>
        <description>The Cystic Fibrosis Questionnaire-Revised (CFQ-R) is a validated health-related quality of life measure for CF that meets US Food and Drug Administration psychometric requirements for patient reported outcomes. It contains both generic and CF-specific scales and has demonstrated responsiveness in previous clinical studies. Scores range from 0 to 100 with higher scores indicating better health.</description>
        <time_frame>Day 0 to Day 6 or upon discharge from the hospital, whichever comes first</time_frame>
        <population>Results could not be reported for 4 participants due to missing baseline data in one case, missing followup data in one case, and no CFQ-R data in two cases.</population>
        <group_list>
          <group group_id="O1">
            <title>Experimental Therapy</title>
            <description>High-Flow, 20 LPM (via Optiflow cannula) Heated (34C) Humidified Air&#xD;
High-Flow, 20 LPM (via Optiflow cannula): Nasal high flow humidification (20LPM) therapy will be administered using Optiflow with Airvo 2.</description>
          </group>
          <group group_id="O2">
            <title>Control Therapy (Low Flow)</title>
            <description>Low FLow, 5 LPM (via Optiflow cannula) Room Temperature (23-26C) Ambient Air&#xD;
Low FLow, 5 LPM (via Optiflow cannula): standard humidified wall medical air.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Cystic Fibrosis Questionnaire-Revised (CFQ-R)</title>
          <description>The Cystic Fibrosis Questionnaire-Revised (CFQ-R) is a validated health-related quality of life measure for CF that meets US Food and Drug Administration psychometric requirements for patient reported outcomes. It contains both generic and CF-specific scales and has demonstrated responsiveness in previous clinical studies. Scores range from 0 to 100 with higher scores indicating better health.</description>
          <population>Results could not be reported for 4 participants due to missing baseline data in one case, missing followup data in one case, and no CFQ-R data in two cases.</population>
          <units>change in score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Physical functioning subscale</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.056" spread="0.105"/>
                    <measurement group_id="O2" value="0.052" spread="0.152"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vitality subscale</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.192" spread="0.139"/>
                    <measurement group_id="O2" value="0.194" spread="0.115"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Emotional state subscale</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.089" spread="0.139"/>
                    <measurement group_id="O2" value="0.033" spread="0.087"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Social limitations subscale</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.056" spread="0.096"/>
                    <measurement group_id="O2" value="-0.028" spread="0.154"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Role limitations subscale</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.056" spread="0.192"/>
                    <measurement group_id="O2" value="0.010" spread="0.175"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Body image subscale</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.037" spread="0.170"/>
                    <measurement group_id="O2" value="0.125" spread="0.192"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Eating disturbances subscale</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.037" spread="0.280"/>
                    <measurement group_id="O2" value="0.097" spread="0.162"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Treatment constraints subscale</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.037" spread="0.170"/>
                    <measurement group_id="O2" value="-0.097" spread="0.093"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Respiratory symptoms subscale</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.019" spread="0.170"/>
                    <measurement group_id="O2" value="-0.125" spread="0.856"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Digestive symptoms subscale</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.111" spread="0.192"/>
                    <measurement group_id="O2" value="0.028" spread="0.098"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Weight subscale</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.222" spread="0.192"/>
                    <measurement group_id="O2" value="0.083" spread="0.236"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Health status subscale</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.083" spread="0.399"/>
                    <measurement group_id="O2" value="0.000" spread="0.103"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Sputum Collection</title>
        <description>Sputum is collected during pulmonary function test (PFT) to later measure the biophysical properties of cystic fibrosis sputum.</description>
        <time_frame>10 minutes</time_frame>
        <population>We were unable to collect sputum samples from the participants</population>
        <group_list>
          <group group_id="O1">
            <title>Experimental Therapy</title>
            <description>High-Flow, 20 LPM (via Optiflow cannula) Heated (34C) Humidified Air&#xD;
High-Flow, 20 LPM (via Optiflow cannula): Nasal high flow humidification (20LPM) therapy will be administered using Optiflow with Airvo 2.</description>
          </group>
          <group group_id="O2">
            <title>Control Therapy (Low Flow)</title>
            <description>Low FLow, 5 LPM (via Optiflow cannula) Room Temperature (23-26C) Ambient Air&#xD;
Low FLow, 5 LPM (via Optiflow cannula): standard humidified wall medical air.</description>
          </group>
        </group_list>
        <measure>
          <title>Sputum Collection</title>
          <description>Sputum is collected during pulmonary function test (PFT) to later measure the biophysical properties of cystic fibrosis sputum.</description>
          <population>We were unable to collect sputum samples from the participants</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Length of hospital stay - up to 3 months</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Experimental Therapy</title>
          <description>High-Flow, 20 LPM (via Optiflow cannula) Heated (34C) Humidified Air&#xD;
High-Flow, 20 LPM (via Optiflow cannula): Nasal high flow humidification (20LPM) therapy will be administered using Optiflow with Airvo 2.</description>
        </group>
        <group group_id="E2">
          <title>Control Therapy (Low Flow)</title>
          <description>Low FLow, 5 LPM (via Optiflow cannula) Room Temperature (23-26C) Ambient Air&#xD;
Low FLow, 5 LPM (via Optiflow cannula): standard humidified wall medical air.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Product Issues</title>
            <event_list>
              <event>
                <sub_title>Nasal discomfort</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Bruce K. Rubin MEngr, MD, MBA, FRCPC</name_or_title>
      <organization>Virginia Commonwealth University</organization>
      <phone>804 828 9604</phone>
      <email>bruce.rubin@vcuhealth.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

